Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $56.82, for a total value of $14,205.00. Following the sale, the vice president now owns 56,738 shares in the company, valued at approximately $3,223,853.16. The sale was disclosed in a filing with the SEC, which is available through this link.

Meredith Cook also recently made the following trade(s):

• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.62, for a total value of $14,905.00.
• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.91, for a total transaction of $16,227.50.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ ANIP opened at $61.05 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The company has a 50-day moving average price of $61.22 and a 200-day moving average price of $63.78. The stock has a market capitalization of $1.28 billion, a P/E ratio of 38.16 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company’s quarterly revenue was up 18.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.06 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on ANIP shares. Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday. Truist Financial reiterated a “hold” rating and set a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $78.80.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Innealta Capital LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $65,000. Ridgewood Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at about $85,000. SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at about $106,000. ADAR1 Capital Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $132,000. Finally, Clear Street Markets LLC bought a new stake in ANI Pharmaceuticals in the 4th quarter worth about $140,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.